CAMPHOR (SYNTHETIC)

US Approved OTC

First marketed in 1921

Details

Stereochemistry	RACEMIC
Molecular Formula	C10H16O
Molecular Weight	152.2334
Optical Activity	( + / - )
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2

InChI

InChIKey=DSSYKIVIOFKYAU-XCBNKYQSSA-N

InChI=1S/C10H16O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7H,4-6H2,1-3H3/t7-,10+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C10H16O
Molecular Weight	152.2334
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://naturaldatabase.therapeuticresearch.com/nd/PrintVersion.aspx?id=709 | http://www.webmd.com/vitamins-and-supplements/camphor-uses-amd-risks | http://www.sciencedirect.com/science/article/pii/B9780123864543007041

Camphor is a bicyclic monoterpene ketone found widely in plants, especially cinnamomum camphora. Topically, camphor is used to relieve pain. It has been used to treat warts, cold sores, hemorrhoids, and osteoarthritis. It has also been applied topically as an analgesic and an antipruritic. It has been used as a counterirritant, and to increase local blood flow. Camphor has frequently been used topically to treat respiratory tract diseases involving mucous membrane inflammation. It is sometimes used topically to treat cardiac symptoms. Camphor is also used topically as an eardrop, and for treating minor burns. In inhalation therapy, camphor is used as an antitussive. Orally, camphor is used as an expectorant, antiflatulent, and for treating respiratory tract diseases. Today, most camphor is synthetic. It is approved by the FDA as a topical antitussive. Camphor is produced synthetically from the oil of turpentine. It has been used for centuries for its medicinal features, in religious rituals, and in cooking. It is no longer used as pesticide. In 1982, the US Food and Drug Administration restricted commercial products intended for medicinal use to contain <11% camphor.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Potency
Transient receptor potential cation channel subfamily A member 1 38 Target ID: CHEMBL6007 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25897313	Antagonist 2849	1.26 mM [IC50]
Vanilloid receptor 53 Target ID: CHEMBL5102 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16192383 \| https://www.ncbi.nlm.nih.gov/pubmed/25897313	Agonist 2752
Transient receptor potential cation channel subfamily V member 3 12 Target ID: CHEMBL5522 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16192383 \| https://www.ncbi.nlm.nih.gov/pubmed/25897313	Agonist 2752

Conditions

Condition	Modality	Highest Phase	Product
Pain 619 Sources: https://www.drugs.com/cdi/camphor-ointment.html http://www.webmd.com/vitamins-and-supplements/camphor-uses-amd-risks	Palliative	Approved 8583	Camphor ointment Approved Use Camphor ointment is used for: Treating pain and itching associated with minor skin irritations. Camphor ointment is a topical analgesic. It works by temporarily relieving itching and pain.
Cough 106 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c4d08cc6-e424-40ae-9c9b-5d5b1619377a&type=display http://www.webmd.com/vitamins-and-supplements/camphor-uses-amd-risks	Primary	Approved 8583	CAMPHOR, EUCALYPTUS OIL AND MENTHOL - camphor, eucalyptus oil and menthol ointment CVS Approved Use Uses - on chest and throat, temporarily relieves cough due to common cold - On muscles and joints, temporarily relieves minor aches and pains
Muscle pain 7 Sources: https://www.drugs.com/pro/tetramex-spray.html	Palliative	Approved 8583	Tetramex Spray Approved Use INDICATIONS AND USAGE: For temporary relief of minor aches and pains of the muscles and joints associated with simple backache, arthritis, strains, bruises and sprains.

C_max

Value	Dose	Co-administered	Analyte	Population
41 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342616/	374.4 mg single, topical dose: 374.4 mg route of administration: Topical experiment type: SINGLE co-administered: MENTHOL, UNSPECIFIED FORM	MENTHOL, UNSPECIFIED FORM	[NO STEREO] CAMPHOR, (-)-\|[NO STEREO] CAMPHOR (SYNTHETIC)\|[NO STEREO] CAMPHOR (NATURAL) plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
302 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342616/	374.4 mg single, topical dose: 374.4 mg route of administration: Topical experiment type: SINGLE co-administered: MENTHOL, UNSPECIFIED FORM	MENTHOL, UNSPECIFIED FORM	[NO STEREO] CAMPHOR, (-)-\|[NO STEREO] CAMPHOR (SYNTHETIC)\|[NO STEREO] CAMPHOR (NATURAL) plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
6.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15342616/	374.4 mg single, topical dose: 374.4 mg route of administration: Topical experiment type: SINGLE co-administered: MENTHOL, UNSPECIFIED FORM	MENTHOL, UNSPECIFIED FORM	[NO STEREO] CAMPHOR, (-)-\|[NO STEREO] CAMPHOR (SYNTHETIC)\|[NO STEREO] CAMPHOR (NATURAL) plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P003PPK
AbovChem LLC	HY-B1173
Acros Organics	10819
Acros Organics	16464
Acros Organics	22784
AK Scientific	5739AF
Alfa Chemistry	A10708
Alfa Chemistry	A10936
Alfa Chemistry	ACM76222
Bide Pharmatech	BD123522
BioSynth	Q-200785
BioSynth	W-109539
BioSynth	W-110530
BLD Pharm	BD123522
BOC Sciences	21368-68-3
BOC Sciences	76-22-2
Chem Scene	CS-4779
ChemShuttle	141803
Chemspace	CSC000759907
Combi-Blocks	QE-0007
eMolecules	482330
Enamine	BBV-175078
Enamine	EN300-84949
Fluorochem	94195
Fluorochem	94196
Frontier Scientific Services	500030259
HongKong Chemhere	SCA29141
IBScreen	BB_NC-00198
IBScreen	BB_NC-02664
IBScreen	STOCK1N-66758
Indofine	25342
Lab Network	LN00241548
mcule	MCULE-4378124154
mcule	MCULE-8475137009
MedChem Express	HY-B1173
Molnova	M14559
MolPort	MolPort-001-793-333
Oakwood	94195
Sigma Aldrich	02070595\|SIAL
Sigma Aldrich	05-1200\|SAJ
Sigma Aldrich	20506\|SIAL
Sigma Aldrich	21300\|SIAL
Sigma Aldrich	W223023
TargetMol	T0882
Tetrahedron	TS10230
TimTec	SBB012351
TimTec	ST069333
Toronto Research Chemicals	C165800
W&J PharmaChem	50C271904
ZINC	ZINC000000967520	http://zinc15.docking.org/substances/ZINC000000967520

PubMed

Title	Date	PubMed
Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.	2001-05	11295057
Monochloramine inhibits etoposide-induced apoptosis with an increase in DNA aberration.	2001-04-15	11295536
Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients.	2001-04-15	11291056
Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: relation with their sensitivity to CTP-11.	2001-04-13	11299781
DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells.	2001-04-13	11292338
Inhibitory effect of berberine on the mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma.	2001-04-10	11248416
A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide.	2001-04	11279278
Validation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry.	2001-04	11268051
Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.	2001-04	11259359
Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats.	2001-03-12	11245909
Hippocampal neurons of mice deficient in DNA-dependent protein kinase exhibit increased vulnerability to DNA damage, oxidative stress and excitotoxicity.	2001-03-05	11245929
Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.	2001-03-01	11280753
Irinotecan in the treatment of colorectal cancer: clinical overview.	2001-03-01	11230497
Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.	2001-03-01	11230496
Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice.	2001-03	11290871
[A case of AFP-producing gastric cancer responding to low-dose CPT-11 and low-dose cisplatin combination chemotherapy].	2001-03	11265410
Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons.	2001-03	11261509
Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.	2001-02-15	11245461
Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.	2001-02-15	11241238
Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma.	2001-02-15	11241237
Novel cytotoxic 7-iminomethyl and 7-aminomethyl derivatives of camptothecin.	2001-02-12	11212094
North Central Cancer Treatment Group--Mayo Clinic trials in colon cancer.	2001-02	11273589
Modulation of camptothecin analogs in the treatment of cancer: a review.	2001-02	11261892
Adjuvant therapy of colon cancer.	2001-02	11254865
[Weekly low dose CPT-11 for multiple lung metastases of colon cancer on an out-patient treatment: a case report].	2001-02	11235190
Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts.	2001-02	11234891
Why drugs fail: of mice and men revisited.	2001-02	11234873
Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer.	2001-02	11232943
Different susceptibilities of postmitotic checkpoint-proficient and -deficient Balb / 3T3 cells to ICRF-193, a catalytic inhibitor of DNA topoisomerase II.	2001-02	11223549
High-Performance liquid chromatographic analysis of lactone and hydroxy acid of new antitumor drug, DX-8951 (exatecan), in mouse plasma.	2001-02	11217088
Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.	2001-02	11207057
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.	2001-01-15	11212277
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.	2001-01-15	11212269
Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.	2001-01-15	11212241
The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison.	2001-01	11272292
A novel genetic screen identifies checkpoint-defective alleles of Schizosaccharomyces pombe chk1.	2001-01	11270571
New state of the art in small-cell lung cancer.	2001-01	11221023
Current status of irinotecan in lung cancer.	2001-01	11221022
Irinotecan: summary and future directions.	2001-01	11221021
Docetaxel followed by gemcitabine and irinotecan in solid tumors.	2001-01	11221020
Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer.	2001-01	11221019
Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule.	2001-01	11221018
Establishment of the standard regimen for non-small-cell lung cancer in Japan.	2001-01	11221016
Irinotecan in small-cell lung cancer: the US experience.	2001-01	11221015
Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11.	2001	11291833
Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.	2001	11291829
Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.	2001	11244327
Treatment of extensive stage small cell lung cancer.	2001	11224990
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.	2001	11224988
Chemoradiation in locally advanced non-small cell lung cancer.	2001	11224987

Patents

Sample Use Guides

In Vivo Use Guide

Dosing: Adult Cough: Inhalation: Inhale via vaporizer up to 3 times per day. Pain: Topical cream: Apply to affected area up to 4 times per day for 2 weeks. For maximum benefit, use daily for at least 2 weeks and continue to use daily as needed thereafter. Pruritus/Pain: Topical gel: Apply to affected area up to 3 to 4 times per day.

Route of Administration: Topical

In Vitro Use Guide

1 mM camphor partially inhibited the AITC (20 uM)-induced hTRPA1 current in HEK293T cells expressing hTRPA1.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:48:32 GMT 2025` Edited by `admin` on `Mon Mar 31 18:48:32 GMT 2025`
Record UNII	5TJD82A1ET
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CAMPHOR, RACEMIC

Preferred Name

English

CAMPHOR (SYNTHETIC)

Common Name

English

CAMPHOR, DL-

Common Name

English

2-BORNANONE

Systematic Name

English

DL-CAMPHOR

Common Name

English

(±)-CAMPHOR

Systematic Name

English

CAMPHOR, (±)-

Systematic Name

English

1,7,7-TRIMETHYLBICYCLO(2.2.1)HEPTAN-2-ONE

Systematic Name

English

FEMA NO. 4513

Code

English

(1RS,4RS)-1,7,7-TRIMETHYLBICYCLO(2.2.1)HEPTAN-2-ONE

Systematic Name

English

BICYCLO(2.2.1)HEPTANE-2-ONE, 1,7,7-TRIMETHYL-

Systematic Name

English

GUM CAMPHOR

Common Name

English

CAMPHOR, RACEMIC [EP MONOGRAPH]

Common Name

English

2-CAMPHANONE

Systematic Name

English

DL-CAMPHOR [JAN]

Common Name

English

Camphor [WHO-DD]

Common Name

English

SYNTHETIC CAMPHOR

Common Name

English

CAMPHOR [MI]

Common Name

English

CAMPHOR [HSDB]

Common Name

English

Code System Code Type Description

DAILYMED

5TJD82A1ET